Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis

• Status: Completed
• Trial end date: 2011-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the efficacy, safety, and tolerability of ACT-128800 in patients with relapsing-remitting multiple sclerosis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Actelion
• Treatments: Ponesimod

Criteria

Inclusion Criteria:

• Adult males and females

• Diagnosis of RRMS as defined by the revised (2005) McDonald Diagnostic Criteria for Multiple Sclerosis (MS).

• Signed inform consent prior to initiation of any study-mandated procedure.

Exclusion Criteria:

• A diagnosis of MS categorized as primary progressive or secondary progressive or progressive relapsing.

• Patients currently treated for an autoimmune disorder other than MS.

• Contraindications for MRI.

• Ongoing bacterial, viral, or fungal infection.

• History or presence of malignancy.

Additional inclusion and exclusion criteria apply with respect to medical conditions and concomitant treatments which could affect patients' risk from participating in the study.